Last reviewed · How we verify
NCT06623903: EMETA
Early Changes in Metabolic Health in Breast Cancer Patients Initiating Endocrine Therapy
trial in Early Breast Cancer in 112 participants. Not yet recruiting.
31 July 2025
Quick facts
| Lead sponsor | Aarhus University Hospital |
|---|---|
| Status | Not yet recruiting |
| Study type | OBSERVATIONAL |
| Enrollment | 112 |
| Start date | 1 November 2024 |
| Primary completion | 31 July 2025 |
| Estimated completion | 31 July 2025 |
| Sites | 1 location across Denmark |
Conditions studied
- Early Breast Cancer — all drugs for Early Breast Cancer →
- Metabolic Health — all drugs for Metabolic Health →
- Estrogen Receptor Positive Breast Cancer — all drugs for Estrogen Receptor Positive Breast Cancer →
Sponsor
Aarhus University Hospital
Who can join
18 and older, any sex, with Early Breast Cancer or Metabolic Health. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This clinical trial aims to investigate early metabolic health changes in early breast cancer patients that initiate antihormone therapy. Furthermore, how these changes are affected by estrogen level, treatment type, and patient characteristics. The hypothesis is, that initiation of antihormone therapy for early breast cancer patients is associated with an early deterioration in metabolic health after 3 months. This includes increased BMI (Body Mass Index), waist- and hip circumference, blood pressure, blood sugars, and lipids compared to when the patients initiate antihormone therapy. Concurrently, estradiol levels are expected to decrease. An estimated 112 patients initiating antihormone therapy at the Dept. of Oncology, Aarhus University Hospital (AUH) will be included in the study over 6 months from autumn 2024. Patients will have a metabolic screening on the day of initiating antihormone therapy and at 3-month antihormone treatment follow-up. The two metabolic screenings each consists of biometric measurements and a blood sample.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Exploring the Impact of Initiating Endocrine Therapy on Metabolic Health in Early Breast Cancer: Protocol for the Prospective Follow-Up EMETA-Study.
Nissen L, Busk Holm J, Borgquist S. · · 2026 · PMID 41880605 · DOI 10.2196/78589
Verify or expand the search:
- PubMed search for NCT06623903
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Early Breast Cancer
Currently open trials in the same condition.
- NCT07233928 — Breast Cancer Organelle Properties and Protein Expression Atlas in the Three Immunohistochemical Subtypes of Breast Canc · NA · recruiting
- NCT07327021 — MRI-Guided Neoadjuvant Treatment De-Escalation in Stage II-III TNBC · Phase 2 · recruiting
- NCT06984250 — Hypofractionated Radiotherapy With Concomitant Tumor Bed Boost for Breast Cancer · recruiting
- NCT06650423 — Adherence to Aromatase Inhibitors ± Abemaciclib Treatment in Patients With Early-stage HER2-negative Breast Cancer · recruiting
- NCT05827081 — Phase IIIb Study of Ribociclib + ET in Early Breast Cancer · Phase 3 · recruiting
Other Aarhus University Hospital trials
Trials by the same sponsor.
- NCT07432802 — Sublobar Wedge Resection or Stereotactic Radiotherapy Treatment of High-risk Patients With Early-stage Lung Cancer · NA · not yet recruiting
- NCT07499336 — UNDERSTANDING THE T-CELL AND B-CELL RECEPTOR REPERTOIRE IN CHILDREN AND YOUNG ADULTS WITH ANTI-DRUG ANTIBODIES AGAINST P · not yet recruiting
- NCT07454486 — TRACE-BTC. Relation of Biomarkers and Patients Reported Quality of Life to Outcomes in Patients With Biliary Tract Cance · not yet recruiting
- NCT07284069 — Senicapoc and Perampanel for Newly Diagnosed Glioblastoma · EARLY_PHASE1 · recruiting
- NCT07426250 — Clinical Utility of ctDNA in the Treatment of Oligometastatic Disease · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06623903 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Aarhus University Hospital
- Last refreshed: 2 October 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06623903.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing